T he past three decades have witnessed substantial progress in clinical islet transplantation (1) (2) (3) (4) for patients with type 1 diabetes mellitus (T1DM) and hypoglycemia unawareness (5) (6) (7) (8) (9) . There is no conclusive data currently available on the role of antibody-mediated rejection in the setting of allogeneic islet transplantation. Anti-human leukocyte antigen (HLA) antibodies can develop after exposure to allogeneic tissues through blood transfusion, pregnancy, or previous transplantation (10) . The importance of alloantibody-mediated rejection has been recognized for solid organ transplants (11) . Antibodies reacting with HLA expressed by kidney allografts can induce hyperacute and/or acute vascular rejection that frequently result in transplant failure (12) . Scattered cases of HLA sensitization measured as positive panel reactive antibodies (PRA) preceding or associated with loss of islet graft function have been described in patients with T1DM bearing kidney allografts (islet after kidney [IAK] or simultaneous islet-kidney [SIK] transplantation) in the 1980s and 1990s (13) (14) (15) . Recent data have shown that pretransplant PRAϩ is associated with reduced survival of islet alone transplantation (ITA) (16) . Interestingly, lack of allosensitization after ITA has been described, despite infusion of islets isolated from multiple donors (5, 8, 17) , a phenomenon that may relate to efficacy of the new immunosuppressive regimens utilized (5, 7, 8, 17) . Loss of islet graft function may occur with the development of donor HLA sensitization (18) , even in the absence of PRAϩ in recipients of either ITA or IAK (15, 19) . Notably, IAK graft loss occurred without jeopardizing the function of the transplanted kidney (15, 19) . A positive association between allosensitization and islet graft loss (dysfunction or rejection) has been described in only few sequential ITA recipients (17, 20, 21) , particularly in presensitized recipients (21) . (Table 1 ). All trials were approved by the UM Institutional Review Board (IRB) and/or Western IRB (Olympia, WA). The trials have been grouped based on the era the transplants were performed, either before (Table 2) or after (Table 3 ) the year 2000. Inclusion criteria were similar among the trials: T1DM Ͼ5 years, age 18 -65 years, negative C-peptide (Ͻ0.3 ng/ml by radioimmunoassay) in response to a mixed meal tolerance test (MMTT), and stable diabetes complications.
Islet Isolation and Transplantation
Islets were isolated using the automated method (22, 23) and purification on discontinuous and/or continuous density gradients (24, 25) from human pancreata obtained after cerebral death from heartbeating donors. Islets were transplanted by percutaneous transhepatic cannulation of the portal vein (26, 27) or by access of a mesenteric tributary of the portal system after laparotomy (28) .
Monitoring of Graft Function
Graft function was monitored by evaluating exogenous insulin requirements, glycated hemoglobin (A1c), and basal and stimulated C-peptide. Metabolic tests performed at baseline and follow-up included MMTT, intravenous glucose tolerance test, and intravenous arginine (7, 28, 29) . Insulin independence was achieved when recipients were able to maintain A1c Յ6.5%, without exogenous insulin administration, with capillary fasting and postprandial blood glucose levels maintained at Յ7.8 mmol/L (140 mg/dL) and Յ10 mmol/L (180 mg/dL), respectively. Graft dysfunction was considered in C-peptide-positive recipients having fasting capillary glucose Ͼ7.8 mmol/L and/or postprandial capillary glucose Ͼ10.0 mmol/L in Ն3 occasions in 1 week, requiring reintroduction of exogenous insulin therapy, confirmed by a 90-min glucose level Ն10.0 mmol/L after MMTT (7, 29) . Graft failure was considered in patients with negative stimulated C-peptide (Ͻ0.3 ng/mL) during the follow-up and/or after discontinuation of immunosuppression (29, 30) .
Bone Marrow Cell Isolation
Bone marrow cells (BMC) were obtained from the vertebral bodies of the same donor of the islets (Table 1) in trials aiming at the induction of hematopoietic chimerism (31) (32) (33) . In selected protocols, enrichment of CD34ϩ stem cells was obtained by positive selection using magnetic beads. The BMC inoculum was cryopreserved and then infused intravenously on days 5 and 11 after islet transplantation.
HLA Typing, Panel Reactive Antibodies, and Crossmatching

Complement-Dependent Cytotoxicity (CDC) Assay
The screening of sera for HLA-I and HLA-II antibodies was performed with a complement-dependent microlymphocytotoxic technique using a commercial kit (Lambda Cell Tray; OneLambda, Canoga Park, CA). Cross-matching of recipient serum with donor cells at the time of transplant was accomplished as previously reported (34) .
Enzyme-Linked Immunosorbent Assay (ELISA)
Serum PRA activity to HLA-I and HLA-II was determined using OneLambda antigen tray-mixed (LAT-M) standardized HLA-ELISA (OneLambda) (35) .
FlowPRA and LABScreen Assays
Alloantibodies were detected by the means of flow cytometry techniques (Luminex Corporation, Austin, TX) using the fluorescent signal for each HLA-coated bead and normalized to the signal of negative control serum (36) . The signal was considered positive when exceeding the cut-off value set by the manufacturer (OneLambda). The strength of a test sample was expressed by the fluorescence value. Percent positive of a test sample was calculated by dividing the number of positive beads by the total number of beads tested as per manufacturer's instructions (36) .
Screening for HLA Antibodies and Donor-Recipient Matching Criteria
Donor and recipient HLA typing and cross-matching were tested prior to initiation of immunosuppression and/or islet transplant. A negative serum donor-recipient crossmatch and ABO compatibility was required at the time of transplant. All recipients were routinely tested for lymphocytotoxic PRA before and after transplantation, as well as after graft loss or immunosuppression discontinuation. Standard PRA screening was based on the CDC assay for all trials performed before the year 2000. In the present study, we have retested samples archived from patients in recent clinical trials using CDC, ELISA and flow cytometry. The cutoff for a PRAϩ in the present study was Ͼ20%.
Donor-Specific and Nondonor-Specific Antibodies
Serum specificities were determined by CDC and ELISA using the LAT HLA-I and HLA-II reagents (OneLambda). The flow PRA tests can detect antibodies and their HLA specificities in each Labscreen panel. The single-antigen assay allows confirmation of antibody specificity suggested by a previous PRA test. Patients were considered PRAϩ whenever antibodies against HLA-I and/or HLA-II donor-specific (DS) or not donor-specific (NDS) were detected by at least one test. It was presumed that subjects with HLA antibodies by ELISA/Luminex and negative CDC had complement-nonfixing antibodies, but they were equally considered as having DS or NDS antibodies (37) .
Statistical Analysis
Data was analyzed using Microsoft Excel, Statistica 6.0 (StatSoft, Inc., Tulsa, OK), and SigmaPlot 9.0 (Systat Software, Inc.; San Jose, CA). Data are presented as meansϮstandard deviation (SD). Statistical significance was considered for PϽ0.05.
RESULTS
Patients
Sufficient data on alloantibody monitoring was available for 66 recipients of islet allografts at our center between 1984 and 2006 (Table 2) . Forty received ITA, 17 IAK, and 9 SIK transplants under the immunosuppressive protocols available in the different years ( Table 1) . Evaluation of PRA in PnDnMn: number of pregancies (P), deliveries (D), and miscarriages (M). the trials performed before the year 2000 (Table 2 ) was based on CDC.
HLA Phenotype of Islet Allograft Recipients and Their Donors
Donor and recipient HLA-I and HLA-II phenotypes were retrospectively analyzed and were not considered as a determinant for transplant. Overall, HLA-A, -B, and -DR matching as well as HLA phenotype of islet allograft recipients is presented for trials performed before and after the year 2000 ( Table 2 ). All grafts had Ն2 mismatches with the recipient and very few alleles were shared between first and subsequent transplants. In particular, only two subjects (4 and 23) shared the same HLA-II with the donor, while none shared HLA-I haplotypes ( Table 2 ). The mean number of HLA mismatches was 7.1Ϯ3.3 (HLA-I: 4.8Ϯ2.3; HLA-II: 2.3Ϯ1.3).
HLA Antibodies Before Islet Transplantation
All 66 subjects were crossmatched negative before islet transplantation; 56 were also PRA-negative by CDC. Of the 10 subjects with a PRAϩ within the 3 months preceding islet infusion, six were SIK (2, 8, 14, 15, 16, and 17), three were IAK (4, 6, and 11), and one was ITA (22) (Table 3 ). Subject 22 was PRAϩ only for HLA-II (28%). Islet graft function was variable (range 21-360 days) in these patients. Subject 4 had graft function for only 1 month. Subject 6 had an allogeneic kidney transplanted for end-stage renal disease (ESRD) 6 years earlier and, despite PRAϩ at baseline (HLA-Iϭ31%, HLA-IIϭ30%), maintained islet graft function up to 360 days. Stable kidney function was observed despite persistence of PRAϩ for HLA-I (islet DSA: A2 and B39) ( Table 4) and HLA-II (range 68 -82%) throughout the follow-up as well as after islet graft loss. Subject 11 had PRAϩ at baseline (HLA-I: 31%; HLA-II: 18%), received 3 allogeneic islet preparations, and tested negative until 9 months after the first islet infusion (HLA-I: 31%; HLA-II: 11%; DSA: B8, B57, DR6 and DR8) ( Table 4) . One month after allosensitization, C-peptide was no longer detectable, while kidney function remained stable. Subject 16 displayed PRAϩ 1 and 6 months after transplantation. While C-peptide was no longer detectable 2 months later (postoperative day, POD 229), kidney graft function remained unchanged and at the most recent follow-up (3 years after islet failure) remains PRA-negative.
Trials performed before the year 2000 were solely based on PRA assessed by CDC, while ELISA and/or flow cytometry were introduced afterwards. Depending on archived specimen availability, sera from selected patients were re-tested to evaluate whether graft outcomes could be attributed to undiagnosed allosensitization by CDC at the time of transplant (Table 3) . This re-analysis identified six additional subjects who previously tested negative by CDC at the time of transplant (subjects 23, 27, 28, 29, 46, and 53), all women with previous pregnancies (range 1-4; Table 2 ). Subject 23 discontinued immunosuppression due to nonadherence to protocol and islet graft function was lost at POD 45 (30) . Islet graft survival for subjects 27 and 29 was 164 and 158 days, respectively, which was shorter than that of other patients in the same trial (I-BMT; mean graft survival 374.7Ϯ161.3 days in this trial). Subject 28 had showed islet allograft function for 471 days, a time similar to that of other patients in the same Evaluation of the impact of pretransplant HLA sensitization on the outcome of islet grafts performed either before and after 2000 showed no significant differences when comparing patients with PRA positive (Ͼ20%) and negative (Ͻ20%) pretransplant (Fig. 1A) . A trend (although not statistically significant) toward a positive correlation of PRAϩ pretransplant and duration of graft function was observed in the patients of trials performed after 2000, although the small number of PRAϩ patients at baseline (nϭ3) may account for this observation. Similarly, the impact of PRAϩ after islet transplantation on graft function showed unremarkable differences in study subjects of trials performed before and after 2000 (Fig. 1B) . Interestingly, in the trials performed before 2000, two patients with PRAϩ maintained long-term graft function (Fig. 1B) .
HLA Antibodies During Follow-Up
Allosensitization Status by CDC
Of the 66 study subjects (all years), only 13 (19.6%) displayed PRAϩ during follow-up. Eight (12%) of them developed PRAϩ de novo and five had PRAϩ pretransplant (Table 3) . No other patients developed a PRAϩ by CDC at any time during the follow-up while on immunosuppression, despite graft loss/dysfunction occurring in some cases (nϭ28). Three of the patients who developed PRAϩ while on immunosuppression (subject 7, 9, and 57) have enjoyed longterm islet graft function. Subject 7 maintained islet graft function for Ͼ13 years (28, 30) and developed PRAϩ 3 years after islet transplant (DSA: A1, A23, B7, B8 and DR9 against both islet donors; Tables 3 and 4 ). Subject 9 received three islet preparations 3 years after a kidney allograft and developed DSA against the three islet donors (DR5, DR6, and DR9) 180 days after transplantation (Table 4) . Islet function persisted for Ͼ13 years (28, 30) . Kidney rejection occurred 11 years after IAK; therefore azathioprine and cyclosporine were discontinued, while maintaining methylprednisolone (MP). Sustained C-peptide was detectable until death at POD 4,492. One year after kidney rejection, sensitization occurred only for HLA-II (range 32-44% by CDC), despite MP maintenance. Subject 57 received two sequential islet infusions 12 years after an allogeneic kidney (2002-05 trial). Forty-two months after the second islet infusion, he displayed PRAϩ by CDC (HLA-I: 34%; HLA-II: 63%), which coincided with an EBV infection. Two months before developing PRAϩ, MP was tapered and discontinued. At the present time (Ͼ2 months from PRAϩ detection), stable islet and kidney graft function is maintained under target trough levels of immunosuppression. In the seven SIK-BMC transplants (1994 -96 trial; Table 1), overall islet graft function was 140Ϯ55 days (range 64 -229). Subject 18 developed PRAϩ by CDC 1 month after SIK transplantation (HLA-I: 98%; HLA-II: 18%). After hepatitis C diagnosis, interferon (IFN)-␣ treatment was implemented at POD 45, resulting in prompt rejection of both islet and kidney grafts (30) . Notably, kidney allograft survival in the patients in this trial was Ͼ600Ϯ170 days with wellpreserved renal function (creatinine 0.3 mg/dl, nϭ6) and with no episodes of renal rejection at the follow up, despite loss of C-peptide.
Subject 60 (2002-05 IAK trial) received a single islet infusion 4.5 years after kidney allotransplantation. Due to severe adverse events (pneumonia and severe skin lesions) requiring hospitalization 6 months after islet implantation, sirolimus trough levels were reduced, resulting in resolution of the complications. Development of PRAϩ for HLA-I and subsequent loss of islet graft function were recorded soon after (POD 284), while kidney graft function was maintained. Subjects 27 and 29 were discussed earlier, with islet graft function of 178 and 158 days, respectively. Subject 10 (1990 -93) showed graft function for 154 days (Table 3) .
Different immunosuppressive regimens have been utilized in the different trials considered in this study. We have therefore grouped the trials based on the time of introduction of more powerful immunosuppression based on sirolimustacrolimus maintenance in the year 2000 (5, 7, 30) . In the trials before 2000, 37.5% (9/24) of subjects displayed PRAϩ by CDC while on immunosuppression (subjects 4, 6, 7, 9, 10, 11, 16, 18, and 23; Table 3 ). By contrast, only 9.5% (4/42) of patients after 2000 displayed PRAϩ by CDC while on immunosuppression (subjects 27, 29, 57, and 60; Table 2 ); only 7/42 subjects were IAK, with the majority being ITA (nϭ27) and I-BMT (nϭ8). Notably, in trials performed before 2000, the majority of the cases were IAK (nϭ10) or SIK (nϭ9).
For 41 patients transplanted after year 2000, PRA data assessed by CDC, ELISA, and Flow while on immunosuppression was available. All had persistent C-peptides, but required reintroduction of exogenous insulin after graft dysfunction (7) . Seven (17%) displayed PRAϩ by any of the different tests while on immunosuppression (subjects 27, 28, 29, 46, 53, 57 , and 60; Table 3 ). Only three of them (7%) developed PRAϩ de novo (subjects 53, 57, and 60, discussed earlier), while the others were positive pretransplant.
HLA Sensitization After Immunosuppression Withdrawal
Retesting of sera specimens from a total of 35 patients participating in 1998 trials of ITA and I-BMT was performed using a combination of CDC, ELISA, and Flow PRA. Thirtytwo subjects (91%) were PRA-negative while on immunosuppression based on any of the methods (mean follow-up 708Ϯ581 days). A total of 16 subjects discontinued immunosuppression and withdrew from the trials (per protocol, nϭ4; voluntary, nϭ6; or due to adverse events, nϭ6) (7, 30, 38) . Sufficient serum samples for reanalysis were available for 14/16 patients (ELISA and Flow; CDC in only 12 subjects; suppressive drugs (on), and after immunosuppression withdrawal (off). PRA-negative by CDC was recorded at the time of transplant in all 16 subjects. Retesting of specimens from 14 of these subjects showed that one subject (28) was PRAϩ by CDC (HLA-I: 21%), ELISA (HLA-I: 80%; HLA-II 42%), and Flow (HLA-I: 73%; HLA-II 40%; Figure 2) .
During follow-up and while on immunosuppression, only three subjects were PRAϩ (subjects 27, 28, and 29; Fig.  2 ). Data for PRA by CDC was available for only 12 patients. Subject 27 displayed PRAϩ in the borderline values by CDC (HLA-I: 21%) and ELISA (HLA-I: 20%) with frankly positive Flow (HLA-I: 31%). Subject 28 was PRA-negative by CDC but frankly positive by ELISA (HLA-I: 79%; HLA-II: 56%) and Flow (HLA-I: 84%; HLA-II: 77%). Subject 29 displayed PRAϩ by CDC (HLA-I: 46%) that was not confirmed by ELISA and Flow (HLA-I: 10% and 0%, respectively) on the same specimen (Fig. 2) .
After drug withdrawal (POD 133Ϯ68, range 29 -287 days), PRAϩ for HLA-I by CDC was observed in 58.3% (7/12) of patients for whom data was available (HLA-I: 24.25Ϯ25.9%), while 41.6% (nϭ5) remained PRA-negative ( Figure 2 ). Evaluation of PRA by ELISA and Flow showed that all 14 patients for whom data was available were positive (Ͼ20% PRA) for both HLA-I (ELISA: 79.3Ϯ23.9%; Flow: 74Ϯ23%) and HLA-II (ELISA: 55.7Ϯ37.2%; Flow: 58.6Ϯ24.8; Figure 2 ).
Development of Donor-Specific Antibody
When evaluating only the recipients of ITA and I-BMT performed after 1998 (nϭ35; Table 2), we have identified five subjects (22, 23, 28, 42 , and 63) with donor-specific antibody (DSA) positive before islet transplantation all of which were negative while on immunosuppressive treatment, with only one exception (subject 23; Table 4 ). Subject 28 presented with DSA again after discontinuation of immunosuppressive therapy (Table 4) . Only subjects 23 and 25 had DSA during follow-up while on immunosuppression (Table 4) . Development of DSA to Ն1 donor HLA occurred in 75% (12/16) of the patients after discontinuation of immunosuppression (Table 4) . Development of alloantibody against HLA not specific for any of the islet donors was also detected in these patients (Table 4) .
DISCUSSION
The deleterious impact of PRAϩ at the time of transplant on the outcome of solid organ grafts has been recognized (10). Similar observations have been reported in the setting of islet transplantation (13, 14, 16, 19, 20) . Collectively, even though functional impairment of the islet allograft was observed in some cases of PRAϩ recipients (8, 21) , a cause-relationship could not be formally established on a large number of observations thus far (18) .
In the present study, we have retrospectively evaluated the development of alloantibodies in patients with T1DM who underwent allogeneic islet transplantation at our institute over the last 22 years. In our series of transplants performed before the year 2000, one IAK patients maintained a functional islet graft for Ͼ1 year, despite baseline PRAϩ. Two IAK recipients who developed PRAϩ with DSA while on immunosuppression maintained islet allograft function for Ͼ13 years (28, 30) . Six SIK recipients (1994 -96 trial) maintained excellent kidney graft function for Ͼ600 days without episodes of rejection, despite loss of islet graft function.
After 2000, three I-BMT recipients appeared PRAϩ at the retesting of baseline samples by ELISA and Flow. All remained PRAϩ during follow-up while under immunosuppression: two of them lost graft function within 5 months, while one showed sustained function while under immunosuppression. A recent report demonstrated a negative association of pretransplant PRAϩ and the outcome of ITA (16) . Further studies on larger cohorts of patients will allow for the conclusive assessment of the impact of basal PRAϩ on the fate of islet allografts.
The development of PRAϩ after islet transplantation has been associated with impairment of graft function measured as reduction of C-peptide during metabolic testing (13) and overall metabolic control assessed by the Ryan ␤-score (17) . Loss of islet graft function has also been reported after allosensitization in islet transplant recipients (14, 20) . In our study, most patients remained PRA-negative while on immunosuppression (7), with 11 cases (7 before and 4 after the year 2000) displaying PRAϩ by CDC in association with lowering of immunosuppression trough levels and/or infection episodes.
Development of DSA associated with loss of allogeneic islet function has been reported in experimental transplantation (39) and in a recent clinical case (18) . In our series, DSAϩ was detected in selected patients both before and after islet transplantation, although no definitive association with graft outcome could be determined from our analysis.
The lack of PRAϩ in our recent trials in patients under adequate immunosuppressive management indicates that the therapeutic protocols utilized may have effectively prevented alloantibody production. Notably, most of the trials were based on high trough levels of sirolimus and low doses of tacrolimus (7, 30) , which might have contributed to this observation. Furthermore, our data suggests that monitoring of PRA may not have great value if therapeutic levels of immunosuppressive drugs are achieved, as reported earlier (15) . The use of antidonor mixed lymphocyte reaction in vitro has been recently proposed as a valuable tool for the immune monitoring of islet allograft recipients as it could be associated to graft dysfunction in islet allograft recipients (15, 40, 41) .
Retesting of archived sera by CDC, ELISA, and Flow demonstrated that a number of samples resulting negative or borderline by CDC were frankly positive by the other methods. It has been suggested that CDC may be less sensitive for the detection of allosensitization and that ELISA and Flow maybe more suitable and reproducible to perform (42) . Our old trials relied on PRA by CDC, and this may have contributed to misdiagnose previous allosensitization in some cases. Indeed, we have observed that selected patients who displayed PRAϩ at baseline when retesting was performed with the new technology maintained positive values during the follow-up under immunosuppression, which may have contributed, at least in some cases, to the poor islet graft outcome recorded.
The most striking data emerging from the present study is the invariable development of allosensitization in virtually all patients who discontinued immunosuppression. This
